Company profile
C4 THERAPEUTICS, INC.
NASDAQ:CCCCBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SENDEGOBRESIB | phase1 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05355753 | phase1 | terminated | 2022-03-25 | 2023-12-19 | C4 Therapeutics, Inc. | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors |
| NCT05668585 | phase1 | completed | 2022-12-08 | 2025-11-05 | C4 Therapeutics, Inc. | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors |
| NCT07284758 | phase2 | recruiting | 2026-02-18 | 2030-03-01 | C4 Therapeutics, Inc. | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |
| NCT07280013 | phase1 | recruiting | 2026-02-06 | 2028-12-01 | C4 Therapeutics, Inc. | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects |
| NCT04756726 | phase1 | active_not_recruiting | 2021-04-27 | 2026-09-30 | C4 Therapeutics, Inc. | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma |
FDA applications (0)
No records yet.